Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cereno Scientific strengthens its Executive Management Team with recruitment of Head of Preclinical Development

Cereno Scientific (XSAT: CRNO B) today announced that Nick Oakes has been appointed as Head of Preclinical Development. The appointment brings significant experience within preclinical research and development in cardiovascular disease, a key factor for the success of Cereno’s continued pipeline development.“I am excited to welcome Nick to Cereno and believe he will be a strong complement to our Executive Management Team. His long-standing experience within preclinical drug development will be instrumental as our preclinical programs continue advancing towards Phase I IND submission,” says

SKF announces launch of SKF Axios powered by AWS

New condition monitoring offer provides anomaly detection solution for a wider range of applications and customers. SKF Axios will be exhibited during Hannover Messe 2022.Gothenburg, 30 May 2022: Today, SKF launched SKF Axios, a solution which reinvents the fields of industrial machine reliability and predictive maintenance based on a collaboration between SKF and Amazon Web Services, Inc. (AWS). SKF will exhibit SKF Axios in the AWS booth (Hall 5, Booth A54) at Hannover Messe 2022, from 30 May to 2 June. Manufacturers want to use simple and affordable wireless technology to monitor more

Rejlers expands in wind park monitoring

Rejlers expands its services to the booming wind power sector with monitoring services 24/7. Through the acquisition of the Finnish Loiste Group's wind monitoring business, Rejlers can now help customers across the Nordic region in the energy transition, where major investments are being made in wind power.“Through our monitoring centre in Kajaani, Finland, we can help customers in all the Nordic countries. The energy transition and movement to renewable energy entail major investments in wind power in the Nordic region. Securing safe connections is critical and we support our customers in

SSAB participates in “Industry Transition Dialogue” in connection with the UN conference Stockholm+50

SSAB has been invited to participate in LeadIT's and World Economic Forum's meeting "Industry Transition Dialogue" on June 1, as well as in a number of other events in connection with the UN conference Stockholm+50.Industry Transition Dialogue is held before the international UN meeting Stockholm+50 "A healthy planet for all - our responsibility, our opportunity" taking place in Stockholm on 2-3 June 2022, with Sweden as host. Industry Transition Dialogue includes Sweden’s Climate and Environment Minister Annika Strandhäll, India's Environment Minister Bhupender Yadav and Anthony Hobley,

RLS Global increases its presence in the Middle East

RLS Global strengthens its presence in the Middle East. Through a regional agent, Med Surg, the company will establish a local distribution network in Egypt, Saudi Arabia, Iraq, Lebanon, Qatar, the United Arab Emirates, Oman and Jordan.The fact that RLS Global is establishing a network for the distribution of ChloraSolv, is an important step to obtain regulatory approval in the eight countries. The regulatory processes are estimated to take about three to twelve months, depending on the country. As soon as ChloraSolv is regulatory approved in a specific country, the commercial process

Mohammed Salloum appointed interim Chief Operating Officer of Intrum

Mohammed Salloum has been appointed interim Chief Operating Officer (COO) of Intrum, effective 1 June 2022. Harry Vranjes, who has been COO since 2020, will leave Intrum for a position outside the company.Mohammed Salloum has, in his role as Chief Transformation Program Officer, been leading Intrum’s transformation program since January 2021 and joined Intrum as Group Finance Director in August 2020. Mohammed has previously held positions specialized in finance and strategy at companies such as McKinsey & Company, Hemfrid AB, Capgemini Consulting and Volvo Group.  “With Mohammed Salloum

Realhearts CEO Elected to the ISMCS Board of Trustees

Press release 20 May, 2022 Realheart's CEO Ina Laura Perkins has been elected to the Board of Trustees of the International Society for Mechanical Circulatory Support, ISMCS. The announcement was made at the society's annual conference in Hannover, Germany, May 24 to 27.The ISMCS is an international forum for discussion of the research, development, clinical use and social acceptance of rotary blood pumps and related forms of mechanical circulatory support. The aim is to improve the quality of life for patients and provide cost-effective availability of emerging therapies. At least

PharmNovo submits CTA for neuropathic pain drug candidate

PharmNovo has submitted a clinical trial application (CTA) to the Swedish Medical Products Agency and Ethical Review Authority to start a phase I study of its neuropathic pain drug candidate PN6047. The company's preclinical program has been completed with good results regarding safety and efficiency. The drug candidate is thus ready to be tested in a first-in-human study.Neuropathic pain, or nerve pain, affects nearly ten percent of the population in Europe and the United States. It is a difficult-to-treat form of pain that often develops into a chronic condition and significantly impairs

The subscription period in Alzinova’s rights issue starts today

Today, on 30 May 2022, the subscription period begins for Alzinova AB’s (publ) (“Alzinova” or the “Company”) rights issue of unit consisting of shares and warrants, which was announced on 19 April 2022 (the “Rights Issue”). The subscription period in the Rights Issue runs up to and including 13 June 2022. However, please note that nominees may have a deadline for subscription in the Rights Issue that falls before 13 June 2022.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA,

Notice to the Annual General Meeting of Loudspring Plc

Loudspring Plc Company Release                                     30 May 2022 at 9.00 (EET) Notice to the Annual General Meeting of Loudspring Plc Notice is given to the shareholders of Loudspring Plc to the Annual General Meeting to be held on Monday, 20 June 2022 at 10.00 (EET) at Radisson Blu Royal, address Runebergikatu 1, 00100 Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 9.30 (EET). A. Matters on the agenda of the Annual General Meeting At the Annual General Meeting, the

Aiforia Technologies Plc: Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies Plc Company Release 30 May 2022 09.00 a.m. EEST Aiforia Technologies Plc — Managers’ Transactions_______________________________________________   Person subject to the notification requirement   Name: Tapaninen, Jukka   Position: Chief Executive Officer   Issuer: Aiforia Technologies Plc   LEI: 743700TJRVBX7420Y723   Notification type: INITIAL NOTIFICATION   Reference number: 15589/5/4   _______________________________________________   Transaction date: 25.5.2022   Venue: FIRST NORTH GROWTH MARKET

Presentation of Biomarker Analysis at ASCO

Faron Pharmaceuticals Ltd (“Faron or Company”)   Faron Announces Presentation of Biomarker Analysis at 2022 ASCO Annual Meeting Showing PromisingClinical Benefit of Bexmarilimab in Patients with Low PD-L1 and High Clever-1 Levels   · Biomarker analyses indicate that the tumors of patients benefitting from treatment with bexmarilimab had: · statistically significant higher levels of Clever-1 positive intra-tumoral cells · low PD-L1 levels, a population that does not typically respond to or is ineligible for treatment with currently approved checkpoint inhibitors

SBB sells a development property for approximately SEK 55 million to Järngrinden

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has sold a property in Borås for an agreed property value of approximately SEK 55 million to the property company Järngrinden. The property being sold is a development property / building rights. For further information, please contact:Oscar Lekander, Deputy CEO and Chief Operating Officer, Samhällsbyggnadsbolaget i Norden AB, oscar@sbbnorden.se

Norway Royal Salmon ASA to proceed with the acquisition of SalmoNor AS and merge with SalMar ASA

Trondheim, 30 May 2022 · Norway Royal Salmon ASA (“NRS”) and SalMar ASA (“SalMar”) (“the Parties”) have entered into a merger plan whereby the two entities will merge, with SalMar as the acquiring company in the merger (the “Merger”). · The agreed exchange ratio is based on the average volume weighted closing share price of SalMar from 4 April to 20 May 2022. Based on an exchange ratio of 0.369 shares in SalMar per share in NRS, this results in a value of NOK 265.18 per NRS share, which gives a premium of 6.3% to the NRS closing price Friday 27 May 2022, and 12.1% to NRS’ average

EG7 executive team and select board members purchase additional company stock

On May 25, 2022, the EG7 executive team and select board members purchased 2,446,592 shares, representing 2.8% of outstanding shares, from Robin Flodin, the former CEO of EG7. The purchase price was SEK 16.25 per share and amounted to almost SEK 40 million. After this transaction, Mr. Flodin will no longer be a shareholder in the company. The purchasing group was led by Jason Epstein, a current board member and the proposed new chairman of the board who acquired 1.1 million shares; Ji Ham, the acting CEO, acquired 900,000 shares, doubling his stake; and Alexander Albedj, the current

Skanska redevelops army vehicle storage facility in the West of England, UK, for GBP 259M, about SEK 3.2 billion

Skanska has signed a contract with the Defence Infrastructure Organisation to redevelop a British Army vehicle storage and maintenance facility based in the West of England, UK. The contract is worth GBP 259M, about SEK 3.2 billion, which will be included in the order bookings for Europe for the second quarter of 2022.Skanska will deliver the construction, along with mechanical and electrical engineering services of new storage buildings, workshops and an office. It will see a complex programme of demolition of 58 buildings, construction of 12 new buildings and refurbishment of one existing

SynAct Pharma publishes Q1 2022 interim report

SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the first quarter 2022.“During the first quarter, we made important decisions regarding the continued development of AP1189 and not least secured financing for the next development phase. We have prepared to be able to start important studies in RA shortly, have been active in business development and have prepared for listing of the share on Nasdaq,” said Jeppe Øvlesen, CEO. January – March 2022 · The Group’s net sales amounted to SEK 0 (0) thousand, which is in line with expectations given the phase the

The subscription price for the exercise of warrants of series TO 3 in Dicot AB has been set to 0.29 SEK per share

Press release: Uppsala, May 29, 2022. During the fourth quarter of 2021, Dicot AB (publ) (``Dicot`` or ``the Company``) conducted a rights issue of units, with one (1) unit consisting of three (3) new issued shares and three (3) free-of-charge warrants of series TO 3 (previously also named series 2021/2022). Those who subscribed for units during the subscription period between October 12, 2021, and October 27, 2021, therefore obtained three (3) additional warrants of series TO 3 per unit subscribed. Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in Dicot.

Scout Gaming Group bridge financing finalized

Scout Gaming Group has during the evening reaching an agreement with some of the major shareholders concerning a bridge financing, at market interest rate, to solve the liquidity for the coming months. The company will within the near future inform concerning the work which was initiated last week concerning capital raising going forward. For additional information, please contact:Andreas Ternström, CEOTel: +46 706 770 660E-mail: andreas.ternstrom@scoutgaminggroup.comNiklas Jönsson, CFOTel: +46 725 494 173E-mail: niklas.jonsson@scoutgaminggroup.com About Scout Gaming

RhoVac’s phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint

RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, regrets to announce today on May 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 (onilcamotide) superiority over placebo in preventing progression in patients with biochemical recurrence (a rise in PSA) after curative intent therapy. Progression was defined as either a doubling of PSA, clinical recurrence, or death. RhoVac will undertake a more thorough analysis of the results, and a clear plan on how to proceed will be

$1 Psychic Reading Online: What To Expect

If you're curious about $1 psychic readings, you may be wondering what to expect. Psychic reading is a process in which a psychic reader attempts to read the energy of a person and their surroundings. This can provide insights into the past, present, and future. Most people who receive $1 psychic readings find them to be beneficial and insightful. However, it's essential to keep in mind that not all psychic readings are accurate. Go To The Best Psychic Reading Sites >>  There are a number of different factors that can influence the accuracy of

Nordea Bank Abp: Repurchase of own shares on 27.05.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares27.05.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 27.05.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number Weighted average Total cost, EUR* **venue (MIC of price / share, EUR* Code) shares **XSTO 110,504 9.81 1,083,825.13XHEL 106,353 9.80 1,042,248.76CEUX 237,034 9.80 2,323,912.64AQEU 26,052 9.81 255,691.08

There are no items matching the current filter
There are no more items matching the current filter
Back to top